Hvað þýðir "Hreinsa"?
Dýrið ber ekki stökkbreytinguna. Það mun ekki þróa sjúkdóminn og mun ekki gefa það áfram.
Hundur Hrörnun hunda í mörgum kerfum í kínverskum krumma (CMSD-CC)
The Canine Multiple System Degeneration (CMSD) DNA test is essential for Chinese Crested dog owners and breeders. CMSD is a hereditary neurological disorder affecting this breed, leading to progressive loss of coordination and mobility. Early genetic testing helps identify carriers and affected dogs, enabling responsible breeding decisions to reduce disease incidence. By using the CMSD DNA test, breeders can ensure healthier litters and improve the overall well-being of Chinese Crested dogs. This test is simple, accurate, and vital for maintaining the breed’s genetic health. Protect your Chinese Crested with reliable CMSD DNA testing today. Stay informed and promote a healthier future for your pets.
Skammstöfun: CMSD-CC
Grein stökkbreyting: SERAC1 c.128+1_128+4delGTAA
Erfðir: Autosomal víkjandi
Skammstöfun
CMSD-CC
Athuguð tíðni
Klínísk alvarleiki
Klínísk flokkun
Taugasjúkdómar
Greind stökkbreyting
SERAC1 c.128+1_128+4delGTAA
Erfðamáti
Autosomal víkjandi
Próf samantekt:
The DNA test for Canine Multiple System Degeneration (CMSD) in Chinese Crested dogs helps identify carriers and affected individuals. CMSD is a hereditary neurological disorder that leads to progressive loss of coordination and muscle control. Early detection through genetic testing allows breeders to make informed decisions and reduce the risk of passing the disease to offspring. This test is essential for maintaining the health and quality of the Chinese Crested breed. Responsible breeding practices supported by DNA testing contribute to healthier future generations.
Fáanlegt úr pakkanum: Basic
Þetta DNA próf er innifalið frá pakkanum okkar Basic — og er líka hluti af pökkunum Basic, Standard, Advanced, Complete.
Skoða DNA prófunarpakka →Veldu pakkann sem passar best við ræktunar- eða heilsustefnu dýranna þinna.
Understanding Canine Multiple System Degeneration (CMSD)
Canine Multiple System Degeneration (CMSD) is a progressive neurological disorder primarily affecting Chinese Crested dogs. This condition is characterized by a degeneration of nerve cells in multiple systems within the body, leading to a variety of symptoms that can significantly impact the quality of life of affected dogs.
Symptoms of CMSD
The symptoms of CMSD can vary widely among affected individuals but typically include a combination of motor dysfunction, coordination issues, and cognitive decline. Common signs may involve difficulty walking, tremors, and a general lack of coordination. As the disorder progresses, dogs may exhibit weakness in their limbs, making it challenging for them to perform routine activities such as running or jumping.
Causes and Genetic Basis
CMSD is believed to be genetically inherited, with specific mutations in the DNA linked to the condition. These mutations disrupt normal cellular functions, leading to the degeneration of nerve cells. Researchers are actively studying the genetic factors associated with CMSD to better understand its pathogenesis and to develop potential targeted therapies.
Diagnosis of CMSD
Diagnosis of CMSD typically involves a combination of clinical evaluations and genetic testing. Veterinarians will assess the dog's neurological function and may recommend imaging or other diagnostic tools to rule out other potential causes of the symptoms. Genetic testing can confirm the presence of mutations associated with CMSD, aiding in a definitive diagnosis.
Stjórnunar- og meðferðarúrræði
Currently, there is no cure for CMSD; however, management strategies aim to improve the quality of life for affected dogs. Supportive care may include physical therapy to maintain mobility, nutritional support to ensure proper health, and medications to manage symptoms such as pain or anxiety. Regular veterinary check-ups are essential to monitor the dog's condition and adjust care as needed.
Importance of Genetic Testing
Genetic testing plays a crucial role in understanding CMSD and managing the health of Chinese Crested dogs. By identifying carriers of the mutation, breeders can make informed decisions to minimize the risk of this condition in future generations. Additionally, early detection through genetic testing can lead to proactive management of affected dogs, ultimately improving their quality of life.
Tegund viðurkennd fyrir prófið: Hrörnun hunda í mörgum kerfum í kínverskum krumma (CMSD-CC)
- Chinese Crested
🧬 Interpretation of genotypes CMSD-CC
Arfgerð
Staða
🟡 N/N
Ekki flutningsaðili - Engin áhætta
🟡 N/CMSD-CC
Flutningsaðili - Engin áhætta
❌ CMSD-CC/CMSD-CC
Fyrir áhrifum - í hættu
Algengar spurningar: skilja túlkunina
Er „flutningsaðili“ alvara?
Nei. Dýrið er almennt heilbrigt en getur sent stökkbreytinguna til þess afkvæmi.
Hvað ef dýr hefur „áhrif“?
Það ber tvö stökkbreytt eintök. Búist er við klínískum einkennum eftir því sjúkdómnum. Það ætti ekki að rækta það.
Af hverju er munur á karli / konu?
Sumir sjúkdómar eru kyntengdir, þannig að tjáning þeirra er mismunandi eftir því kynlíf dýra.
Spáðu í afkvæmi
N/N (ekki-flutningsadili)
N/CMSD-CC (Flytjandi)
CMSD-CC/CMSD-CC (Fyrir áhrifum)
Algengar spurningar um DNA próf
Hvað greinir þetta DNA próf?
This DNA test detects the mutation associated with Canine Multiple System Degeneration In Chinese Crested (CMSD-CC) in order to identify clear, carrier, or at-risk animals.
Af hverju að prófa ræktunardýr?
DNA próf hjálpar ræktendum að skipuleggja öruggari pörun og draga úr hættu á að stökkbreytingin berist til afkvæma.
Hver er arfleifð þessa prófs?
Erfðastillingin sem tilkynnt er um fyrir þetta próf er Autosomal Recessive.
Hvaða stökkbreyting er greind í þessu prófi?
This test analyses the mutation SERAC1 c.128+1_128+4delGTAA.
Er burðardýr endilega fyrir áhrifum?
Ekki endilega. Túlkun fer eftir erfðamynstri og arfgerðinni sem myndast.
Heimildir
Johnson GS, Mhlanga-Mutangadura T, Morava E, Kozicz T, Taylor JF, O’Brien DP, Schnabel RD. Canine Multiple System Degeneration is Associated with Distinct SERAC1 Mutations in Two Different Dog Breeds [abstract]. Presented at the 63rd Annual Meeting of the American Society of Human Genetics in Boston, Massachusetts; 2013 Oct 22-26.